Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 and announced discovery of its first potential Covid-19 candidate two weeks later on May 4, 2020.
View full press release